UA56132C2
(uk)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
US6231859B1
(en)
|
1996-12-02 |
2001-05-15 |
Aquila Biopharmaceuticals, Inc. |
Saponin adjuvant compositions
|
WO1998024319A1
(en)
*
|
1996-12-02 |
1998-06-11 |
Aquila Biopharmaceuticals, Inc. |
Novel saponin compositions and uses thereof
|
WO1999010008A1
(en)
*
|
1997-08-29 |
1999-03-04 |
Aquila Biopharmaceuticals, Inc. |
Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
|
GB9817052D0
(en)
*
|
1998-08-05 |
1998-09-30 |
Smithkline Beecham Biolog |
Vaccine
|
EP1104306B1
(de)
|
1998-08-10 |
2006-01-11 |
Antigenics Inc. |
Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
|
AUPP807399A0
(en)
*
|
1999-01-08 |
1999-02-04 |
Csl Limited |
Improved immunogenic lhrh composition and methods relating thereto
|
DK2204186T3
(en)
|
1999-02-17 |
2016-07-18 |
Csl Ltd |
Immunogenic complexes, and related methods
|
IL145982A0
(en)
|
1999-04-19 |
2002-07-25 |
Smithkline Beecham Biolog |
Vaccines
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
US8017590B1
(en)
|
1999-10-22 |
2011-09-13 |
Sanofi Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
DE60039715D1
(de)
*
|
1999-11-19 |
2008-09-11 |
Csl Ltd |
Hcv-impfstoff zusammensetzungen
|
EP1282702B1
(de)
|
2000-05-10 |
2006-11-29 |
Sanofi Pasteur Limited |
Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
|
AUPR011700A0
(en)
*
|
2000-09-14 |
2000-10-05 |
Austin Research Institute, The |
Composition comprising immunogenic virus sized particles (VSP)
|
PL211151B1
(pl)
|
2000-10-18 |
2012-04-30 |
Glaxosmithkline Biolog Sa |
Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
|
AU2002254901A1
(en)
|
2001-02-23 |
2002-10-03 |
Smithkline Beecham Biologicals S.A. |
Influenza vaccine formulations for intradermal delivery
|
US7713942B2
(en)
*
|
2001-04-04 |
2010-05-11 |
Nordic Vaccine Technology A/S |
Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
AUPR446801A0
(en)
|
2001-04-18 |
2001-05-17 |
University Of Queensland, The |
Novel compositions and uses therefor
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
SE0202110D0
(sv)
*
|
2002-07-05 |
2002-07-05 |
Isconova Ab |
Iscom preparation and use thereof
|
JP4697706B2
(ja)
|
2002-10-11 |
2011-06-08 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
|
WO2004037189A2
(en)
|
2002-10-23 |
2004-05-06 |
Glaxosmithkline Biologicals S.A. |
Methods for vaccinating against malaria
|
CA3042073C
(en)
|
2003-01-30 |
2022-09-13 |
Novartis Vaccines And Diagnostics S.R.L. |
Injectable vaccines against multiple meningococcal serogroups
|
SE0300795D0
(sv)
|
2003-03-24 |
2003-03-24 |
Isconova Ab |
Composition comprising iscom particles and live micro-organisms
|
JP2007537975A
(ja)
|
2003-06-10 |
2007-12-27 |
ザ ユニバーシティー オブ メルボルン |
免疫調節性組成物、それらについての使用方法およびそれらの製造のための方法
|
SE0301998D0
(sv)
*
|
2003-07-07 |
2003-07-07 |
Isconova Ab |
Quil A fraction with low toxicity and use thereof
|
WO2005032582A2
(en)
|
2003-07-31 |
2005-04-14 |
Chiron Corporation |
Immunogenic compositions for streptococcus pyogenes
|
WO2005033278A2
(en)
*
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
JP4738339B2
(ja)
|
2003-10-02 |
2011-08-03 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
複数の髄膜炎菌血清群についての液体ワクチン
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
EP1682159A4
(de)
|
2003-10-16 |
2010-07-21 |
Stephen John Ralph |
Immunomodulierende zusammensetzungen und ihre verwendungen
|
GB0402131D0
(en)
|
2004-01-30 |
2004-03-03 |
Isis Innovation |
Delivery method
|
EP1722815A1
(de)
|
2004-03-09 |
2006-11-22 |
Chiron Corporation |
Influenza-virus-vakzine
|
EP1740217B1
(de)
|
2004-04-30 |
2011-06-15 |
Novartis Vaccines and Diagnostics S.r.l. |
Meningokokken-konjugat-impfung
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
JP4896021B2
(ja)
|
2004-05-21 |
2012-03-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
呼吸器系病原体ワクチンのためのアルファウイルスベクター
|
ATE491467T1
(de)
|
2004-05-28 |
2011-01-15 |
Glaxosmithkline Biolog Sa |
Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
|
US20090317420A1
(en)
|
2004-07-29 |
2009-12-24 |
Chiron Corporation |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
CA2592627C
(en)
|
2005-01-20 |
2014-02-25 |
Isconova Ab |
Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
NZ561042A
(en)
|
2005-02-18 |
2011-03-31 |
Novartis Vaccines & Diagnostic |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CN101273055B
(zh)
|
2005-04-29 |
2016-03-16 |
葛兰素史密丝克莱恩生物有限公司 |
用于预防或治疗结核分枝杆菌感染的新方法
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
EP1764369A1
(de)
|
2005-09-16 |
2007-03-21 |
Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH |
Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
|
DK179025B1
(da)
|
2005-09-16 |
2017-08-28 |
Intervet Int Bv |
Fiskevaccine
|
CN101355960A
(zh)
|
2005-10-18 |
2009-01-28 |
诺华疫苗和诊断公司 |
使用α病毒复制子颗粒进行粘膜和全身免疫
|
EP1779866A1
(de)
|
2005-11-01 |
2007-05-02 |
Intervet International BV |
"Prime-Boost" Impfstoff zum Schutz von Pferden vor viraler Infektion
|
US10842867B2
(en)
|
2005-11-04 |
2020-11-24 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
CA2630220C
(en)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Norovirus and sapovirus antigens
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
BRPI0707300B8
(pt)
|
2006-01-27 |
2021-05-25 |
Novartis Ag |
vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
AU2007231027B2
(en)
|
2006-03-24 |
2013-10-03 |
Novartis Influenza Vaccines Marburg Gmbh |
Storage of influenza vaccines without refrigeration
|
CA2647942A1
(en)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
EP2035035A2
(de)
|
2006-06-09 |
2009-03-18 |
Novartis AG |
Immunogene zusammensetzungen für streptococcus agalactiae
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2586790A3
(de)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogene von uropathogenen Escherichia coli
|
MX2009002408A
(es)
|
2006-09-11 |
2009-03-20 |
Novartis Ag |
Elaboracion de vacunas para el virus de la influenza sin utilizar huevos.
|
WO2008031878A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH |
A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
|
EP1902727A1
(de)
*
|
2006-09-22 |
2008-03-26 |
Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH |
Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
|
AU2007354917B2
(en)
|
2006-09-26 |
2013-06-06 |
Access To Advanced Health Institute |
Vaccine composition containing synthetic adjuvant
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
EP2094278B1
(de)
*
|
2006-11-20 |
2017-04-05 |
Duecom |
Verwendung von lipidhaltigen teilchen mit quillaja-saponinen zur behandlung von krebs
|
EP2121011B1
(de)
|
2006-12-06 |
2014-05-21 |
Novartis AG |
Impfstoffe mit antigen aus vier stämmen des influenzavirus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
LT2137210T
(lt)
|
2007-03-02 |
2016-12-27 |
Glaxosmithkline Biologicals Sa |
Naujas būdas ir kompozicijos
|
CA2679720A1
(en)
*
|
2007-03-09 |
2008-09-18 |
Merck & Co., Inc. |
Papillomavirus vaccine compositions
|
CA2688284A1
(en)
|
2007-05-25 |
2008-12-04 |
Novartis Ag |
Streptococcus pneumoniae pilus antigens
|
PT2185191E
(pt)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Vacinas contra a gripe com baixo teor de aditivos
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
KR20100068390A
(ko)
|
2007-08-13 |
2010-06-23 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
MX2010002773A
(es)
|
2007-09-12 |
2010-03-31 |
Novartis Ag |
Antigenos mutantes de gas57 y anticuerpos de gas57.
|
EP2062594A1
(de)
|
2007-11-21 |
2009-05-27 |
Wyeth Farma, S.A. |
Impfstoff und immunogene Zusammensetzung gegen den Blauzungenvirus, Verfahren zu deren Verwendung und Verfahren zu deren Herstellung
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CN104292312A
(zh)
|
2007-12-21 |
2015-01-21 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
SI2222710T1
(sl)
|
2007-12-24 |
2016-11-30 |
Id Biomedical Corporation Of Quebec |
Rekombinatni RSV antigeni
|
EP2231257A4
(de)
*
|
2007-12-24 |
2013-11-06 |
Univ Queensland |
Beschichtungsverfahren
|
CA2749347C
(en)
*
|
2008-02-07 |
2018-03-27 |
The University Of Queensland |
Patch production
|
US9579372B2
(en)
|
2008-02-21 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Meningococcal fHBP polypeptides
|
CA2718430A1
(en)
|
2008-03-18 |
2009-09-24 |
Novartis Ag |
Improvements in preparation of influenza virus vaccine antigens
|
WO2009143524A2
(en)
|
2008-05-23 |
2009-11-26 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
CA2760680A1
(en)
*
|
2008-05-23 |
2009-11-26 |
The University Of Queensland |
Analyte detection by microneedle patch with analyte selective reagents
|
CN102223876A
(zh)
|
2008-09-26 |
2011-10-19 |
纳米生物公司 |
纳米乳剂治疗性组合物及其使用方法
|
AU2009325950B2
(en)
|
2008-12-09 |
2013-03-07 |
Pfizer Vaccines Llc |
IgE CH3 peptide vaccine
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
US9265821B2
(en)
|
2009-02-17 |
2016-02-23 |
Glaxosmithkline Biologicals Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
JP2012519482A
(ja)
|
2009-03-06 |
2012-08-30 |
ノバルティス アーゲー |
クラミジア抗原
|
DK2510947T3
(en)
|
2009-04-14 |
2016-03-21 |
Glaxosmithkline Biolog Sa |
Compositions for Immunization against Staphylococcus aureus.
|
WO2010125480A1
(en)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
MX2011012347A
(es)
*
|
2009-05-22 |
2012-02-21 |
Genocea Biosciences Inc |
Vacunas contra virus del herpes simple tipo 2: composiciones y metodos para obtener una respuesta inmunitaria.
|
CA2764374C
(en)
|
2009-06-05 |
2019-11-19 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants
|
CN102802665B
(zh)
|
2009-06-15 |
2015-11-25 |
新加坡国立大学 |
流感疫苗、组合物及使用方法
|
EP2442827B1
(de)
|
2009-06-16 |
2016-01-06 |
The Regents of the University of Michigan |
Nanoemulsionsimpfstoffe
|
MX2012000036A
(es)
|
2009-06-24 |
2012-02-28 |
Glaxosmithkline Biolog Sa |
Vacuna.
|
WO2010149745A1
(en)
|
2009-06-24 |
2010-12-29 |
Glaxosmithkline Biologicals S.A. |
Recombinant rsv antigens
|
EP2451833B1
(de)
|
2009-07-07 |
2018-01-17 |
GlaxoSmithKline Biologicals SA |
Konservierte escherichia-coli-immunogene
|
ES2563730T3
(es)
|
2009-07-15 |
2016-03-16 |
Glaxosmithkline Biologicals S.A. |
Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
|
DK2464658T3
(en)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
RU2518291C2
(ru)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Антигенные tau-пептиды и их применения
|
US20110076300A1
(en)
|
2009-08-27 |
2011-03-31 |
Mariagrazia Pizza |
Hybrid Polypeptides Including Meningococcal fHBP Sequences
|
US20110110980A1
(en)
|
2009-09-02 |
2011-05-12 |
Wyeth Llc |
Heterlogous prime-boost immunization regimen
|
CA2771770A1
(en)
|
2009-09-03 |
2011-03-10 |
Pfizer Vaccines Llc |
Pcsk9 vaccine
|
WO2011030218A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
MY157607A
(en)
*
|
2009-09-10 |
2016-06-30 |
Merial Inc |
New vaccine formulations comprising saponin-containing adjuvants
|
DK2477652T3
(en)
|
2009-09-16 |
2015-07-20 |
Vaxart Inc |
Immunization strategy for the prevention of infection H1Ni
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
EP2483390A2
(de)
|
2009-09-30 |
2012-08-08 |
Novartis AG |
Expression von meningokokken-fhbp-polypeptiden
|
AU2010352695B2
(en)
|
2009-09-30 |
2014-08-21 |
Glaxosmithkline Biologicals S.A. |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
CA2779816A1
(en)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Modified meningococcal fhbp polypeptides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
CA2785585A1
(en)
|
2009-12-22 |
2011-06-30 |
Celldex Therapeutics, Inc. |
Vaccine compositions
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
CA2796314A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Benzonapthyridine compositions and uses thereof
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
EP2576613A1
(de)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Her-2-peptide und impfstoffe
|
CA2800774A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
US9943673B2
(en)
|
2010-07-14 |
2018-04-17 |
Vaxxas Pty Limited |
Patch applying apparatus
|
EP3272359A1
(de)
|
2010-07-23 |
2018-01-24 |
Novavax AB |
Influenza-impfstoff
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
CA2808556A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
JP2013545453A
(ja)
|
2010-11-01 |
2013-12-26 |
ユニバーシティ・オブ・テクノロジー、シドニー |
免疫変調剤およびそれらの使用
|
WO2012074881A2
(en)
*
|
2010-11-24 |
2012-06-07 |
Genocea Biosciences, Inc. |
Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
EP2655389A2
(de)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Verbindungen
|
DK2667892T3
(da)
|
2011-01-26 |
2019-05-13 |
Glaxosmithkline Biologicals Sa |
RSV-vaccineringsprogram
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
NZ616304A
(en)
|
2011-04-08 |
2016-01-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
HUE034673T2
(en)
|
2011-05-13 |
2018-02-28 |
Glaxosmithkline Biologicals Sa |
Pre-fusion Rsv F antigens
|
ES2656050T3
(es)
|
2011-07-06 |
2018-02-22 |
Glaxosmithkline Biologicals Sa |
Composiciones de combinación inmunogénica y usos de las mismas
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
BR112014004162A2
(pt)
|
2011-08-22 |
2018-04-24 |
Cangene Corp |
anticorpos contra clostridium difficile
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
PE20141547A1
(es)
|
2011-09-16 |
2014-10-25 |
Ucb Pharma Sa |
Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
|
EP3311827B1
(de)
|
2011-10-03 |
2023-01-04 |
Canqura Oncology Ab |
Nanopartikel, verfahren zur herstellung und verwendung davon als träger für amphipatische oder hydrophobe moleküle in bereichen der medizin mit verbindungen im zusammenhang mit der krebsbehandlung und lebensmitteln
|
EP2765927B1
(de)
|
2011-10-12 |
2021-02-24 |
Vaxxas Pty Limited |
Abgabegerät
|
CA2854934A1
(en)
|
2011-11-07 |
2013-05-16 |
Novartis Ag |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
WO2013078299A1
(en)
*
|
2011-11-23 |
2013-05-30 |
Genocea Biosciences, Inc. |
Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
|
JP6121436B2
(ja)
|
2011-11-23 |
2017-04-26 |
バイオベン・3・リミテッドBioven 3 Limited |
組換えタンパク質及びそれらの治療的用途
|
CA2857087C
(en)
|
2011-11-28 |
2021-05-25 |
Crucell Holland B.V. |
Influenza virus vaccines and uses thereof
|
WO2013082476A1
(en)
|
2011-11-30 |
2013-06-06 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
TR201908003T4
(tr)
|
2012-02-07 |
2019-06-21 |
Infectious Disease Res Inst |
TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
|
DK2825640T3
(en)
|
2012-03-12 |
2016-08-01 |
Crucell Holland Bv |
BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
CA2867950C
(en)
|
2012-03-22 |
2023-02-21 |
Crucell Holland B.V. |
Vaccine against rsv
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
EP2659907A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
EP2659908A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
EP2659906A1
(de)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Zusammensetzungen
|
SI2850431T1
(en)
|
2012-05-16 |
2018-08-31 |
Immune Design Corp. |
Vaccine against HSV-2
|
ES2820898T3
(es)
|
2012-05-22 |
2021-04-22 |
Glaxosmithkline Biologicals Sa |
Conjugado del serogrupo X de meningococos
|
EP2666785A1
(de)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Auf Komplementfaktor C5a basierender Impfstoff
|
JP2015522580A
(ja)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
免疫学的組成物およびその使用
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
JP2015525794A
(ja)
|
2012-08-06 |
2015-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法
|
EP2703483A1
(de)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 Peptidimpfstoff
|
WO2014043189A1
(en)
|
2012-09-14 |
2014-03-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Conditionally replication deficient herpes viruses and use thereof in vaccines
|
EP4056198A3
(de)
|
2012-09-18 |
2022-12-07 |
GlaxoSmithKline Biologicals SA |
Aussenmembranvesikel
|
EP2903650B1
(de)
|
2012-10-02 |
2018-04-04 |
GlaxoSmithKline Biologicals SA |
Nichtlineare saccharidkonjugate
|
WO2014053612A1
(en)
|
2012-10-03 |
2014-04-10 |
Novartis Ag |
Immunogenic composition
|
PE20151720A1
(es)
|
2013-03-08 |
2015-12-10 |
Crucell Holland Bv |
Vacuna acelular contra pertussis
|
MY187936A
(en)
|
2013-03-15 |
2021-10-29 |
In3Bio Ltd |
Self-assembling synthetic proteins
|
TW201502136A
(zh)
|
2013-03-15 |
2015-01-16 |
Glaxosmithkline Biolog Sa |
疫苗
|
WO2014163558A1
(en)
|
2013-04-01 |
2014-10-09 |
Moreinx Ab |
Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
|
EA032326B1
(ru)
|
2013-04-18 |
2019-05-31 |
Иммьюн Дизайн Корп. |
Монотерапия gla для применения в лечении рака
|
EA039803B1
(ru)
|
2013-04-25 |
2022-03-15 |
Янссен Вэксинс Энд Превеншн Б.В. |
Стабилизированные растворимые f-полипептиды rsv до слияния
|
WO2014191435A1
(en)
|
2013-05-30 |
2014-12-04 |
Crucell Holland B.V. |
Influenza virus vaccines and uses thereof
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
CA2914792C
(en)
|
2013-06-17 |
2024-02-27 |
Crucell Holland B.V. |
Stabilized soluble pre-fusion rsv f polypeptides
|
WO2015000832A1
(en)
|
2013-07-02 |
2015-01-08 |
Crucell Holland B.V. |
Method for preparing virosomes
|
WO2015000831A1
(en)
|
2013-07-02 |
2015-01-08 |
Crucell Holland B.V. |
Method for preparing virosomes
|
EP3492097A1
(de)
|
2013-08-05 |
2019-06-05 |
GlaxoSmithKline Biologicals S.A. |
Immunogene kombinationszusammensetzungen
|
WO2015063611A2
(en)
|
2013-11-01 |
2015-05-07 |
University Of Oslo |
Albumin variants and uses thereof
|
DK3069138T3
(en)
|
2013-11-15 |
2019-04-08 |
Univ Oslo Hf |
CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
BR112016015422A2
(pt)
|
2013-12-31 |
2017-10-24 |
Infectious Disease Res Inst |
formulações de vacina de frasco único
|
NZ759686A
(en)
|
2014-01-21 |
2023-07-28 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
US20170065702A1
(en)
|
2014-02-19 |
2017-03-09 |
Cangene Corporation |
Methods of modulating an immune response
|
US20170224805A1
(en)
|
2014-02-20 |
2017-08-10 |
Vaxart, Inc. |
Formulations for small intestinal delivery
|
BR112016022011A2
(pt)
|
2014-03-26 |
2017-10-24 |
Glaxosmithkline Biologicals Sa |
?antígeno de proteína estafilocócica a mutante, proteína de fusão, e, composição imunogênica?
|
AU2015243246B2
(en)
|
2014-04-10 |
2018-09-06 |
Obi Pharma Inc. |
Antibodies, pharmaceutical compositions and uses thereof
|
MX2016016533A
(es)
|
2014-06-13 |
2017-05-01 |
Glaxosmithkline Biologicals Sa |
Combinaciones inmunogenas.
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
PE20170290A1
(es)
|
2014-07-10 |
2017-03-26 |
Janssen Vaccines And Prevention B V |
Vacunas contra virus de influenza y usos de las mismas
|
WO2016011386A1
(en)
|
2014-07-18 |
2016-01-21 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
JP7158853B2
(ja)
|
2014-10-10 |
2022-10-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物
|
AU2015341926B2
(en)
|
2014-11-04 |
2018-09-27 |
Janssen Vaccines & Prevention B.V. |
Therapeutic HPV16 vaccines
|
KR102149760B1
(ko)
|
2015-01-15 |
2020-08-31 |
화이자 인코포레이티드 |
폐렴구균 백신에서 사용하기 위한 면역원성 조성물
|
EP3253440B1
(de)
|
2015-02-02 |
2022-12-21 |
Vaxxas Pty Limited |
Mikroprojektionsarrayapplikator
|
CA2977493C
(en)
|
2015-03-03 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Display platform from bacterial spore coat proteins
|
WO2016141320A2
(en)
|
2015-03-05 |
2016-09-09 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
AU2016249798B2
(en)
|
2015-04-14 |
2022-05-26 |
Janssen Vaccines And Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
JP2018521016A
(ja)
|
2015-06-03 |
2018-08-02 |
アフィリス・アクチェンゲゼルシャフトAffiris Ag |
IL−23−p19ワクチン
|
AU2016274599B2
(en)
|
2015-06-12 |
2021-09-02 |
Vaxart, Inc. |
Formulations for small intestinal delivery of RSV and norovirus antigens
|
EP3319634B1
(de)
|
2015-07-07 |
2019-08-21 |
Janssen Vaccines & Prevention B.V. |
Stabilisierte lösliche präfusionierte rsv-f-polypeptide
|
DK3319633T3
(da)
|
2015-07-07 |
2021-02-01 |
Janssen Vaccines & Prevention Bv |
Vaccine mod rsv
|
CA2991544A1
(en)
|
2015-07-07 |
2017-01-12 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
TWI756893B
(zh)
|
2015-07-21 |
2022-03-01 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
AU2016309743B2
(en)
|
2015-08-20 |
2019-02-07 |
Janssen Vaccines & Prevention B.V. |
Therapeutic HPV18 vaccines
|
JP6975709B2
(ja)
|
2015-09-02 |
2021-12-01 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
安定化したウイルスクラスi融合タンパク質
|
SG10201913145SA
(en)
|
2015-09-03 |
2020-02-27 |
Novavax Inc |
Vaccine compositions having improved stability and immunogenicity
|
AR105910A1
(es)
|
2015-09-04 |
2017-11-22 |
Obi Pharma Inc |
Matrices de glicano y método de uso
|
CN116063481A
(zh)
|
2015-09-04 |
2023-05-05 |
普里玛托普医疗股份有限公司 |
人源化抗-cd40抗体及其用途
|
EP3138579A1
(de)
|
2015-09-05 |
2017-03-08 |
Biomay Ag |
Fusionsprotein zur behandlung einer infektion durch einen hepatitis-b-virus
|
US11103259B2
(en)
|
2015-09-18 |
2021-08-31 |
Vaxxas Pty Limited |
Microprojection arrays with microprojections having large surface area profiles
|
US10786561B2
(en)
|
2015-11-20 |
2020-09-29 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
EP3393512A1
(de)
|
2015-12-23 |
2018-10-31 |
Pfizer Inc |
Rsv f protein-mutanten
|
WO2017158421A1
(en)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Anti-viral engineered immunoglobulins
|
TN2018000301A1
(en)
|
2016-03-14 |
2020-01-16 |
Univ Oslo |
Engineered immunoglobulins with altered fcrn binding
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
TWI780045B
(zh)
|
2016-03-29 |
2022-10-11 |
台灣浩鼎生技股份有限公司 |
抗體、醫藥組合物及方法
|
AU2017248021B2
(en)
|
2016-04-05 |
2021-08-12 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F proteins
|
AU2017248018A1
(en)
|
2016-04-05 |
2018-09-27 |
Janssen Vaccines & Prevention B.V. |
Vaccine against RSV
|
KR20230110820A
(ko)
|
2016-04-22 |
2023-07-25 |
오비아이 파머 인코퍼레이티드 |
글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
|
CN109922829A
(zh)
|
2016-05-02 |
2019-06-21 |
扬森疫苗与预防公司 |
治疗性hpv疫苗组合
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
MX2018014699A
(es)
|
2016-05-30 |
2019-02-28 |
Janssen Vaccines & Prevention Bv |
Proteinas f de prefusion del vrs estabilizadas.
|
WO2017207477A1
(en)
|
2016-05-30 |
2017-12-07 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv f proteins
|
JP6683847B2
(ja)
|
2016-06-20 |
2020-04-22 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
強力でバランスのとれた双方向性プロモーター
|
WO2017221072A2
(en)
|
2016-06-21 |
2017-12-28 |
University Of Oslo |
Hla binding vaccine moieties and uses thereof
|
EP3484506A1
(de)
|
2016-07-14 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Hpv-impfstoffe
|
WO2018018082A1
(en)
|
2016-07-26 |
2018-02-01 |
The Australian National University |
Immunostimulatory compositions and uses therefor
|
CA3032049C
(en)
|
2016-07-27 |
2023-11-07 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
EP3491026A4
(de)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
|
WO2018037045A1
(en)
|
2016-08-23 |
2018-03-01 |
Glaxosmithkline Biologicals Sa |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
EP3295956A1
(de)
|
2016-09-20 |
2018-03-21 |
Biomay Ag |
Polypeptidkonstrukt mit fragmenten von allergenen
|
US10350288B2
(en)
|
2016-09-28 |
2019-07-16 |
Genocea Biosciences, Inc. |
Methods and compositions for treating herpes
|
BE1024774B1
(fr)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
Compositions et procedes de traitement
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
EP3541414A4
(de)
|
2016-11-21 |
2020-11-11 |
OBI Pharma, Inc. |
Konjugierte biologische moleküle, pharmazeutische zusammensetzungen und verfahren
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
MX2019006349A
(es)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
|
EP3570879B1
(de)
|
2017-01-20 |
2022-03-30 |
Pfizer Inc. |
Immunogene zusammensetzung zur verwendung als pneumokokken-impfstoff
|
AU2018217935B2
(en)
|
2017-02-09 |
2020-04-30 |
Janssen Vaccines & Prevention B.V. |
Potent and short promoter for expression of heterologous genes
|
US11123419B2
(en)
|
2017-03-15 |
2021-09-21 |
Novavax, Inc. |
Methods and compositions for inducing immune responses against Clostridium difficile
|
DK3606760T3
(da)
|
2017-03-31 |
2023-11-06 |
Vaxxas Pty Ltd |
Indretning og fremgangsmåde til belægning af overflader
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
AU2018267971A1
(en)
|
2017-05-17 |
2019-11-07 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against RSV infection
|
WO2018227246A1
(en)
|
2017-06-13 |
2018-12-20 |
Vaxxas Pty Limited |
Quality control of substrate coatings
|
IL300235A
(en)
|
2017-07-18 |
2023-03-01 |
In3Bio Ltd |
Synthetic proteins and their therapeutic uses
|
CN111148509A
(zh)
|
2017-07-24 |
2020-05-12 |
诺瓦瓦克斯股份有限公司 |
治疗呼吸系统疾病的方法和组合物
|
EP3661587A4
(de)
|
2017-08-04 |
2021-06-09 |
Vaxxas Pty Limited |
Kompakter hoher mechanischer energiespeicher und aktuator mit geringer auslösekraft für die abgabe von mikroprojektions-array-patches (map)
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
EP3678699A1
(de)
|
2017-09-07 |
2020-07-15 |
University Of Oslo |
Impfstoffmoleküle
|
US20200276299A1
(en)
|
2017-09-08 |
2020-09-03 |
Infectious Disease Research Institute |
Liposomal formulations comprising saponin and methods of use
|
WO2019053109A1
(en)
|
2017-09-15 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
PT3743106T
(pt)
|
2018-01-23 |
2022-08-24 |
Janssen Vaccines & Prevention Bv |
Vacinas contra o vírus da influenza e suas utilizações
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
MX2020009682A
(es)
*
|
2018-03-19 |
2020-10-12 |
Novavax Inc |
Vacunas de nanoparticulas multivalentes contra la influenza.
|
GB201807303D0
(en)
|
2018-05-03 |
2018-06-20 |
London School Of Hygeine & Tropical Medicine |
Glyconjugate vaccines
|
EP3569612A1
(de)
|
2018-05-18 |
2019-11-20 |
Biomay Ag |
Behandlung und prävention von hausstaubmilbenallergien
|
WO2019224275A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
MX2020013553A
(es)
|
2018-06-12 |
2021-02-26 |
Glaxosmithkline Biologicals Sa |
Polinucleotidos y polipeptidos de adenovirus.
|
EP3581201A1
(de)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 polypeptide und verwendungen davon
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
MX2021001479A
(es)
|
2018-08-07 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Novedosos procesos y vacunas.
|
JP2021534761A
(ja)
|
2018-08-23 |
2021-12-16 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性タンパク質および組成物
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022513025A
(ja)
|
2018-11-13 |
2022-02-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
安定化された融合前rsv fタンパク質
|
US20220016229A1
(en)
|
2018-12-12 |
2022-01-20 |
Pfizer Inc. |
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
|
WO2020128012A1
(en)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Methods of inducing an immune response
|
TW202102256A
(zh)
|
2019-03-05 |
2021-01-16 |
比利時商葛蘭素史密斯克藍生物品公司 |
B型肝炎免疫法及組合物
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
KR20220005002A
(ko)
|
2019-04-25 |
2022-01-12 |
얀센 백신스 앤드 프리벤션 비.브이. |
재조합 인플루엔자 항원
|
MX2021013947A
(es)
|
2019-05-15 |
2021-12-14 |
Janssen Vaccines & Prevention Bv |
Tratamiento profilactico de la infeccion por virus sincitial respiratorio con una vacuna basada en adenovirus.
|
JP2022532723A
(ja)
|
2019-05-15 |
2022-07-19 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与
|
WO2020243115A1
(en)
|
2019-05-25 |
2020-12-03 |
Infectious Disease Research Institute |
Composition and method for spray drying an adjuvant vaccine emulsion
|
KR20220058527A
(ko)
|
2019-06-25 |
2022-05-09 |
인3바이오 리미티드 |
안정화된 키메라 합성 단백질 및 그 치료 용도
|
AU2020318680A1
(en)
|
2019-07-21 |
2022-02-17 |
Glaxosmithkline Biologicals Sa |
Therapeutic viral vaccine
|
JP2022547107A
(ja)
|
2019-09-05 |
2022-11-10 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
インフルエンザウイルスワクチン及びその使用
|
WO2021084429A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
WO2021097347A1
(en)
|
2019-11-15 |
2021-05-20 |
Infectious Disease Research Institute |
Rig-i agonist and adjuvant formulation for tumor treatment
|
US10953089B1
(en)
|
2020-01-27 |
2021-03-23 |
Novavax, Inc. |
Coronavirus vaccine formulations
|
TW202204380A
(zh)
|
2020-01-31 |
2022-02-01 |
美商詹森藥物公司 |
用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
|
JP2023514697A
(ja)
|
2020-02-23 |
2023-04-07 |
ファイザー・インク |
大腸菌組成物およびその方法
|
WO2021229448A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Pharmaceuticals, Inc. |
Rna replicon encoding a stabilized corona virus spike protein
|
CA3183086A1
(en)
|
2020-05-11 |
2021-11-18 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
CN115884786A
(zh)
|
2020-05-11 |
2023-03-31 |
杨森制药公司 |
SARS-CoV-2疫苗
|
WO2021245611A1
(en)
|
2020-06-05 |
2021-12-09 |
Glaxosmithkline Biologicals Sa |
Modified betacoronavirus spike proteins
|
BR112022026408A2
(pt)
|
2020-06-29 |
2023-01-17 |
Janssen Vaccines & Prevention Bv |
Combinação vacinal contra infecção pelo vírus sincicial respiratório
|
BR112022026974A2
(pt)
|
2020-07-06 |
2023-01-24 |
Janssen Pharmaceuticals Inc |
Proteínas de fusão estabilizadas de proteínas de pico de coronavírus
|
JP2022060169A
(ja)
|
2020-10-02 |
2022-04-14 |
ファイザー・インク |
Rsv fタンパク質生産のための細胞培養工程
|
KR20230096033A
(ko)
|
2020-10-27 |
2023-06-29 |
화이자 인코포레이티드 |
에스케리키아 콜라이 조성물 및 그의 방법
|
CN116744965A
(zh)
|
2020-11-04 |
2023-09-12 |
辉瑞大药厂 |
用于肺炎球菌疫苗的免疫原性组合物
|
MX2023006320A
(es)
|
2020-12-02 |
2023-06-14 |
Glaxosmithkline Biologicals Sa |
Cadena donante complementada fimh.
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
EP4032547A1
(de)
|
2021-01-20 |
2022-07-27 |
GlaxoSmithKline Biologicals S.A. |
Hsv1 fce abgeleitete fragemente zur hsv therapie
|
WO2022175479A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Vaccine combinations against respiratory syncytial virus strain a and b infections
|
KR20230147156A
(ko)
|
2021-02-19 |
2023-10-20 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 융합 전 rsv fb 항원
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
CN117320745A
(zh)
|
2021-03-30 |
2023-12-29 |
维拉瓦克斯股份公司 |
Sars-cov-2亚单位疫苗
|
WO2022207793A1
(en)
|
2021-03-31 |
2022-10-06 |
Vib Vzw |
Vaccine compositions for trypanosomatids
|
WO2022207839A2
(en)
|
2021-04-01 |
2022-10-06 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
WO2023046898A1
(en)
|
2021-09-23 |
2023-03-30 |
Viravaxx AG |
Hbv vaccine inducing pres-specific neutralizing antibodies
|
WO2023047348A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized corona virus spike protein fusion proteins
|
WO2023047349A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
WO2023079529A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Re-focusing protein booster immunization compositions and methods of use thereof
|
WO2023079528A1
(en)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
|
WO2023114727A1
(en)
|
2021-12-13 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
WO2023110618A1
(en)
|
2021-12-16 |
2023-06-22 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2023217988A1
(en)
|
2022-05-12 |
2023-11-16 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
WO2024017682A1
(en)
|
2022-07-18 |
2024-01-25 |
Janssen Vaccines & Prevention B.V. |
Rsv immunogens
|
US20240042021A1
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024061757A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Pre-fusion human piv1 f proteins
|
WO2024061759A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized coronavirus s proteins
|
WO2024061753A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized trimeric class i fusion proteins
|
WO2024074584A1
(en)
|
2022-10-06 |
2024-04-11 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|